Status:
UNKNOWN
A Digimed Oncology PharmacoTherapy Registry
Lead Sponsor:
Proteus Digital Health, Inc.
Conditions:
Colon Cancer
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity...
Detailed Description
Patients will be prescribed the DMP and DigiMeds™ (capecitabine or supportive medications) by their healthcare provider. The pharmacy will co-encapsulate the prescribed medication with a sensor. The ...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Prescribed treatment with DigiMeds™
- Have an Android or iOS-enabled device (e.g., iPhone, iPad, Samsung) or be willing to use a Proteus issued iOS device
- Signed consent form
Exclusion
- Receiving palliative or hospice care services (i.e., proxy for \<12 months life expectancy)
- Not proficient in the English language
- Have impaired cognitive ability
- For women: current pregnancy
- Have skin sensitivity to adhesives or active/chronic dermatitis
Key Trial Info
Start Date :
September 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04088955
Start Date
September 6 2019
End Date
March 1 2022
Last Update
March 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carolina Blood and Cancer Care
Rock Hill, South Carolina, United States, 29732